<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01063101</url>
  </required_header>
  <id_info>
    <org_study_id>950901</org_study_id>
    <nct_id>NCT01063101</nct_id>
  </id_info>
  <brief_title>Phase 1 Dosing Study of BAX 513 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Effects of BAX 513 on Hemostatic Parameters in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate whether orally administered BAX 513 (different&#xD;
      doses administered for 5 days) affects hemostatic parameters in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 29, 2010</start_date>
  <completion_date type="Actual">August 1, 2010</completion_date>
  <primary_completion_date type="Actual">July 22, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in peak thrombin concentration from baseline as measured by the Thrombin Generation Assay (TGA).</measure>
    <time_frame>7 months (= anticipated study duration)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>BAX 513</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsule - one of 5 dose levels (per randomization) - BID (= twice a day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capsule (cellulose)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Capsule - one of 5 dose levels (per randomization) - BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fucoidan (extract of Laminaria japonica)</intervention_name>
    <description>Capsule (300 mg/capsule) - oral administration - 5 different dose levels - BID</description>
    <arm_group_label>BAX 513</arm_group_label>
    <other_name>BAX 513</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Cellulose filled capsule - oral administration - 5 different dose levels - BID</description>
    <arm_group_label>Capsule (cellulose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is &gt;= 18 and &lt; 70 years old at the time of screening&#xD;
&#xD;
          -  Is able to provide signed and dated informed consent&#xD;
&#xD;
          -  Is a healthy male or female adult&#xD;
&#xD;
          -  If female and of childbearing potential, subject demonstrates a negative serum&#xD;
             pregnancy test, and agrees to employ adequate birth control measures; (e.g., oral&#xD;
             contraceptives, barrier method) for the duration of the study&#xD;
&#xD;
          -  If female and receiving hormone replacement therapy (HRT), subject agrees to abstain&#xD;
             from HRT for the duration of the study&#xD;
&#xD;
          -  Subject's medical history and physical exam are normal&#xD;
&#xD;
          -  Subject's lab values for complete blood count (CBC) and clinical chemistry are within&#xD;
             normal ranges&#xD;
&#xD;
          -  Is able to comprehend and comply with all aspects of the protocol and signed informed&#xD;
             consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  If female, subject is pregnant or lactating at the time of study enrollment&#xD;
&#xD;
          -  Has participated in another clinical study involving an investigational product (IP)&#xD;
             or device within 30 days of screening or is scheduled to participate in another&#xD;
             clinical study involving an IP or device during the course of this study&#xD;
&#xD;
          -  Has a history of drug allergy in general or hypersensitivity to fucoidan containing&#xD;
             products/foods or seafoods&#xD;
&#xD;
          -  Medical and/or family history of thrombophilic tendencies, eg Protein C or&#xD;
             S-deficiency, ATIII deficiency, FV Leiden mutation, Prothrombin 20210A mutation, lupus&#xD;
             type inhibitor, antiphospholipid antibodies&#xD;
&#xD;
          -  Medical history or clinical findings of a significant bleeding disorder&#xD;
&#xD;
          -  Medical history of thrombotic events such as venous thromboembolism (VTE), myocardial&#xD;
             infarction (MI), stroke or transient ischemic attack (TIA)&#xD;
&#xD;
          -  Any other clinically relevant history of disease, eg malabsorption disorders,&#xD;
             malignancies&#xD;
&#xD;
          -  Any clinically significant abnormal laboratory values or abnormal ECG findings that in&#xD;
             the opinion of the investigator are considered clinically relevant&#xD;
&#xD;
          -  Seropositivity for HBs-Ag, HCV, HIV-1 or HIV-2 antibodies&#xD;
&#xD;
          -  Symptoms of a clinically relevant illness within 3 weeks before screening&#xD;
&#xD;
          -  A history of, or suspected, drug or alcohol abuse, or subject tests positive on a&#xD;
             Drugs of Abuse screen within 1 week of dosing&#xD;
&#xD;
          -  Intake of IP or related (fucoidan-containing) product within 1 week prior to study&#xD;
             enrollment&#xD;
&#xD;
          -  Any planned surgical or dental procedure during the course of this study&#xD;
&#xD;
          -  Any recent surgery within 30 days of enrollment&#xD;
&#xD;
          -  Presence of signs or symptoms consistent with an infection, such as fever, chills, or&#xD;
             nausea during screening in this study&#xD;
&#xD;
          -  Chronic or regular use of aspirin, ibuprofen, coumarin derivatives, antiplatelet&#xD;
             drugs, within 1 week before enrollment&#xD;
&#xD;
          -  Use of concomitant drugs diclofenac or [paracetamol if &gt; 2 g/day] within 1 week before&#xD;
             first day of study dosing&#xD;
&#xD;
          -  Plasmapheresis or platelet donation within 3 weeks of screening and until final visit&#xD;
&#xD;
          -  Any medical condition that may compromise the ability to give written informed consent&#xD;
             or to comply with the study protocol&#xD;
&#xD;
          -  Subject is a member of the team conducting the study or in a dependent relationship&#xD;
             with one of the study team members. Dependent relationships include close relatives&#xD;
             (ie, children, partner/spouse, siblings, parents) as well as employees of the&#xD;
             investigator or site personnel conducting the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Clinic for Clinical Pharmacology, General Hospital Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 4, 2010</study_first_submitted>
  <study_first_submitted_qc>February 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2010</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fucoidan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

